How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    • Has all of the relevant evidence been taken into account?

  • Question on Consultation

    • Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    • Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?
The content on this page is not current guidance and is only for the purposes of the consultation process.

AnaConDa-S for sedation with volatile anaesthetics in intensive care

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1 AnaConDa-S is recommended as an option for delivering inhaled sedation in an intensive care setting when the volatile anaesthetics isoflurane or sevoflurane are being considered.

1.2 Further research is recommended to identify any groups of patients that could benefit from inhaled sedation with AnaConDa-S. Find out more in the section on further research.

1.3 Cost modelling shows that, over 30 days, AnaConDa-S is cost saving compared with intravenous propofol sedation by £4,393.20 per adult. In children, AnaConDa-S is also cost saving compared with intravenous midazolam sedation by £3,396.85 per child. These savings are from reduced time on mechanical ventilation, which may shorten the length of time in intensive care for the patient.

Why the committee made these recommendations

AnaConDa-S is used in intensive care settings when people need inhaled sedation. The evidence for AnaConDa-S includes people with a wide range of conditions. But there were not enough people for each condition in the studies to identify who would particularly benefit from inhaled sedation with AnaConDa-S. Also, there is no published evidence on using AnaConDa-S in children. So, further research is recommended to identify the groups that could benefit from using the technology.

Evidence suggests that time to people waking up from sedation is shorter with inhaled sedation (using AnaConDa-S) than with intravenous sedation, but that a reduction in time on mechanical ventilation is uncertain. It is also uncertain if using AnaConDa-S shortens a person's length of stay in intensive care. Because these are the key drivers of cost savings, the cost analysis results are also uncertain. Even with these uncertainties, AnaConDa-S is still cost saving in both children and adults and shows promise as an option for use in intensive care settings for sedation with volatile anaesthetics, when sedation with isoflurane or sevoflurane is being considered.